BTAI Stock Overview
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BioXcel Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.61 |
| 52 Week High | US$29.56 |
| 52 Week Low | US$1.91 |
| Beta | 0.39 |
| 1 Month Change | -8.74% |
| 3 Month Change | -21.15% |
| 1 Year Change | -87.34% |
| 3 Year Change | -92.43% |
| 5 Year Change | -74.81% |
| Change since IPO | -76.34% |
Recent News & Updates
Recent updates
BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold
Aug 28BioXcel Therapeutics Q2 2022 Earnings Preview
Aug 08BioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great Asset
Jul 19BioXcel's Igalmi: Potential Market For Acute Agitation In Esquizofrenia And Bipolar Patients
May 18Shareholder Returns
| BTAI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.4% | 0.4% | 1.0% |
| 1Y | -87.3% | 0.9% | 21.9% |
Return vs Industry: BTAI underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: BTAI underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| BTAI volatility | |
|---|---|
| BTAI Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BTAI's share price has been volatile over the past 3 months.
Volatility Over Time: BTAI's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 74 | Vimal Mehta | www.bioxceltherapeutics.com |
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
BioXcel Therapeutics, Inc. Fundamentals Summary
| BTAI fundamental statistics | |
|---|---|
| Market cap | US$96.66m |
| Earnings (TTM) | -US$179.05m |
| Revenue (TTM) | US$1.38m |
70.0x
P/S Ratio-0.5x
P/E RatioIs BTAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTAI income statement (TTM) | |
|---|---|
| Revenue | US$1.38m |
| Cost of Revenue | US$1.26m |
| Gross Profit | US$120.00k |
| Other Expenses | US$179.17m |
| Earnings | -US$179.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -4.83 |
| Gross Margin | 8.70% |
| Net Profit Margin | -12,974.86% |
| Debt/Equity Ratio | -178.0% |
How did BTAI perform over the long term?
See historical performance and comparison